This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gavalda, J. Articles by Pahissa, A. Search for Related Content PubMed PubMed Citation Articles by Gavalda, J. Articles by Pahissa, A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, 04 1997, 795-801, Vol 41, No. 4
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

Treatment of experimental pneumonia due to penicillin-resistant Streptococcus pneumoniae in immunocompetent rats

J Gavalda, JA Capdevila, B Almirante, J Otero, I Ruiz, M Laguarda, H Allende, E Crespo, C Pigrau and A Pahissa
Infectious Diseases Research Laboratory, Universitat Autonoma de Barcelona, Spain. gavalda@ar.vhebron.es

A model of pneumonia due to Streptococcus pneumoniae resistant to penicillin was developed in immunocompetent Wistar rats and was used to evaluate the efficacies of different doses of penicillin, cefotaxime, cefpirome, and vancomycin. Adult Wistar rats were challenged by intratracheal inoculation with 3 x 10(9) CFU of one strain of S. pneumoniae resistant to penicillin (MICs of penicillin, cefotaxime, cefpirome, and vancomycin, 2, 1, 0.5, and 0.5 microg/ml, respectively) suspended in brain heart broth supplemented with 0.7% agar. The rats experienced a fatal pneumonia, dying within 5 days and with peak mortality (70 to 80%) occurring 48 to 72 h after infection, and the bacterial counts in the lungs persisted from 8.87 +/- 0.3 log10 CFU/g of lung at 24 h of the infection to 9.1 +/- 0.3 log10 CFU/g at 72 h. Four hours after infection the animals were randomized into the following treatment groups: (i) control without treatment, (ii) penicillin G at 100,000 IU/kg of body weight every 2 h, (iii) penicillin G at 250,000 IU/kg every 2 h, (iv) cefotaxime at 100 mg/kg every 2 h, (v) cefpirome at 200 mg/kg every 2 h, and (vi) vancomycin at 50 mg/kg every 8 h. Two different protocols were used for the therapeutic efficacy studies: four doses of beta-lactams and one dose of vancomycin or eight doses of beta-lactams and two doses of vancomycin. Results of the therapy for experimental pneumonia caused by penicillin-resistant S. pneumoniae showed that initially, all the antimicrobial agents tested had similar efficacies, but when we prolonged the treatment, higher doses of penicillin, cefotaxime, and cefpirome were more effective than penicillin at lower doses in decreasing the residual bacterial titers in the lungs. Also, when we extended the treatment, vancomycin was more efficacious than penicillin at lower doses but was less efficacious than higher doses of penicillin or cefpirome. The model that we have developed is simple and amenable for inducing pneumonia in immunocompetent rats and could be used to explore the pathophysiology and to evaluate optimal therapy of this infection in the immunocompetent host.

This article has been cited by other articles:

• Pichardo, C., Docobo-Perez, F., Pachon-Ibanez, M. E., Jimenez-Mejias, M. E., Garcia-Curiel, A., Caballero-Granado, F. J., Moreno-Maqueda, I., Pachon, J. (2005). Efficacy of {beta}-lactams against experimental pneumococcal endocarditis caused by strains with different susceptibilities to penicillin. J Antimicrob Chemother 56: 732-737 [Abstract] [Full Text]  
• Croisier, D., Etienne, M., Chavanet, P. (2003). Reply. J Antimicrob Chemother 51: 1308-1309 [Full Text]  
• Mitten, M. J., Meulbroek, J., Nukkala, M., Paige, L., Jarvis, K., Oleksijew, A., Tovcimak, A., Hernandez, L., Alder, J. D., Ewing, P., Or, Y. S., Ma, Z., Nilius, A. M., Mollison, K., Flamm, R. K. (2001). Efficacies of ABT-773, a New Ketolide, against Experimental Bacterial Infections. Antimicrob. Agents Chemother. 45: 2585-2593 [Abstract] [Full Text]  
• Erlendsdottir, H., Knudsen, J. D., Odenholt, I., Cars, O., Espersen, F., Frimodt-Møller, N., Fuursted, K., Kristinsson, K. G., Gudmundsson, S. (2001). Penicillin Pharmacodynamics in Four Experimental Pneumococcal Infection Models. Antimicrob. Agents Chemother. 45: 1078-1085 [Abstract] [Full Text]  
• Nicolau, D. P., Onyeji, C. O., Zhong, M., Tessier, P. R., Banevicius, M. A., Nightingale, C. H. (2000). Pharmacodynamic Assessment of Cefprozil against Streptococcus pneumoniae: Implications for Breakpoint Determinations. Antimicrob. Agents Chemother. 44: 1291-1295 [Abstract] [Full Text]  
• Piroth, L., Martin, L., Coulon, A., Lequeu, C., Duong, M., Buisson, M., Portier, H., Chavanet, P. (1999). Development of a New Experimental Model of Penicillin-Resistant Streptococcus pneumoniae Pneumonia and Amoxicillin Treatment by Reproducing Human Pharmacokinetics. Antimicrob. Agents Chemother. 43: 2484-2492 [Abstract] [Full Text]  
• Kaplan, S. L., Mason, E. O. Jr. (1998). Management of Infections Due to Antibiotic-Resistant Streptococcus pneumoniae. Clin. Microbiol. Rev. 11: 628-644 [Abstract] [Full Text]